TRANSTHERA-B-药捷安康-B(02617.HK)：于2026年美国临床肿瘤学会胃肠道肿瘤研讨会公布替恩戈替尼单药治疗晚期胆管癌患者的临床数据

药捷安康-B(02617.HK)：于2026年美国临床肿瘤学会胃肠道肿瘤研讨会公布替恩戈替尼单药治疗晚期胆管癌患者的临床数据

TRANSTHERA-B(HK:02617) Ge Long Hui·2026-01-11 23:14

Core Viewpoint - The company announced the presentation of clinical data for its core product, Tienogratinib, as a monotherapy for patients with advanced cholangiocarcinoma (CCA) at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) [1] Group 1 - The clinical data was presented in a poster format, indicating a significant step in the company's research and development efforts [1]

TRANSTHERA-B-药捷安康-B(02617.HK)：于2026年美国临床肿瘤学会胃肠道肿瘤研讨会公布替恩戈替尼单药治疗晚期胆管癌患者的临床数据 - Reportify